Analyst Price Targets — SUPN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 25, 2026 2:19 pm | — | Craig-Hallum | $65.00 | $57.58 | StreetInsider | Supernus Pharmaceuticals (SUPN) PT Raised to $65 at TD Cowen |
| December 19, 2025 12:50 pm | Annabel Samimy | Stifel Nicolaus | $55.00 | $49.28 | TheFly | Supernus price target raised to $55 from $50 at Stifel |
| October 8, 2025 11:34 pm | — | Piper Sandler | $65.00 | $48.00 | TheFly | Supernus upgraded to Overweight from Neutral at Piper Sandler |
| September 30, 2025 12:42 pm | — | Cantor Fitzgerald | $63.00 | $47.41 | TheFly | Supernus price target raised to $63 from $46 at Cantor Fitzgerald |
| August 29, 2025 10:36 am | — | Piper Sandler | $40.00 | $45.12 | TheFly | Supernus price target raised to $40 from $36 at Piper Sandler |
| July 29, 2025 8:08 pm | — | Cantor Fitzgerald | $42.00 | $33.45 | TheFly | Supernus upgraded to Overweight from Neutral at Cantor Fitzgerald |
| September 11, 2024 4:55 am | David Amsellem | Piper Sandler | $36.00 | $33.49 | TheFly | Piper downgrades Supernus to Neutral on slower Qelbree growth |
| May 24, 2024 7:28 am | David Amsellem | Piper Sandler | $41.00 | $27.85 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Supernus Pharmaceuticals (SUPN) |
| April 8, 2024 10:10 am | Irene Buhalo | Jefferies | $40.00 | $32.27 | StreetInsider | Jefferies on Supernus (SUPN): 'We expect a -5-10% stock reaction after the FDA's rejection of SPN-830' |
| April 8, 2024 10:09 am | Annabel Samimy | Stifel Nicolaus | $38.00 | $32.27 | StreetInsider | Stifel on Supernus Pharmaceuticals (SUPN): 'SPN-830 Approval Delayed Again, but Near-Term Impact Relatively Minor' |
Latest News for SUPN
ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following September investor conferences:
ROCKVILLE, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Professional snowboarder, Chloe Kim, is partnering with Supernus Pharmaceuticals as a compensated ambassador to discuss her journey with attention-deficit/hyperactivity disorder (ADHD) and her treatment plan with Qelbree (viloxazine extended-release capsules), a once-daily, non-stimulant medication for patients 6 years and older. Designed for flexible once-a-day…
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) to Indivior Pharmaceuticals, Inc. for
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) to Indivior Pharmaceuticals, Inc. for 1.5401 common shares of Indivior for each share of Supernus.Halper Sadeh encourages Supernus shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212)…
BlackRock Inc. purchased a new position in Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 9,350,046 shares of the specialty pharmaceutical company's stock, valued at approximately $434,871,000. BlackRock Inc. owned approximately 16.08% of
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SUPN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.